Methods
hypoglycemic, diabetes
DIABETES
Both groups of patients were admitted to the hospital and underwent stringent blood glucose monitoring. All patients did not use other hypoglycemic drugs. During the study period, the patients’ exercise intensity was medium to low, and they followed the diabetes diet. The control group was injected subcutaneously with Liraglutide (Novo Nordisk Pharmaceutical Co., Ltd., China; at the specification 3 mL: 18 mg/stick) at the following regimen: 0.6 mg once a day during the first week before breakfast; then 1.2 mg once a day, from the 2